Indexado en

Licencia y uso

Citaciones

Cited 14 times in

Cited 1 times in

Altmetrics

Grant support

REGESMOHS (Registro Espanol de Cirugia de Mohs) was promoted by Fundacion Piel Sana AEDV, with financial support from Roche Pharma. This publication has received unrestricted financial support from Sun Pharma. Roche Pharma and Sun Pharma have not participated in the design, analysis, or interpretation of the data.

Impacto en los Objetivos de Desarrollo Sostenible (ODS)

Análisis de autorías institucional

Compartir

Risk Factors and Rate of Recurrence after Mohs Surgery in Basal Cell and Squamous Cell Carcinomas: A Nationwide Prospective Cohort (REGESMOHS, Spanish Registry of Mohs Surgery)

Publicado en:Acta Dermato-Venereologica. 101 adv00602- - 2021-11-01 101(), DOI: 10.2340/actadv.v101.544

Autores: Tomas-Velazquez, Alejandra; Sanmartin-Jimenez, Onofre; Garces, Joan R; Rodriguez-Prieto, Manuel A; Ruiz-Salas, Veronica; De Eusebio-Murillo, Esther; Minano-Medrano, Roman; Escutia-Munoz, Begona; Florez-Menendez, Angeles; Artola-Igarza, Juan L; Alfaro-Rubio, Alberto; Gil, Pilar; Delgado-Jimenez, Yolanda; Sanchez-Schmidt, Julia M; Allende-Markixana, Irati; Alonso-Pacheco, Maria L; Garcia-Bracamonte, Beatriz; De la Cueva-Dobao, Pablo; Navarro-Tejedor, Raquel; Ciudad-Blanco, Cristina; Carnero-Gonzalez, Lucia; Vazquez-Veiga, Hugo; Cano-Martinez, Natividad; Vilarrasa-Rull, Eva; Sanchez-Sambucety, Pedro; Lopez-Estebaranz, Jose L; Botella-Estrada, Rafael; Gonzalez-Sixto, Beatriz; Martorell-Calatayud, Antonio; Morales-Gordillo, Victoriano; Toll-Abello, Agusti; Ocerin-Guerra, Izascun; Mayor-Arenal, Matias; Suarez-Fernandez, Ricardo; Sainz-Gaspar, Laura; Descalzo, Miguel A; Garcia-Doval, Ignacio; Redondo, Pedro

Afiliaciones

Resumen

Randomized studies to assess the efficacy of Mohs micrographic surgery in basal cell and squamous cell carcinomas are limited by methodological and ethical issues and a lack of long follow-up periods. This study presents the "real-life" results of a nationwide 7-years cohort on basal cell carcinoma and squamous cell carcinoma treated with Mohs micrographic surgery. A prospective cohort was conducted in 22 Spanish centres (from July 2013 to February 2020) and a multivariate analysis, including characteristics of patients, tumours, surgeries and follow-up, was performed. A total of 4,402 patients followed up for 12,111 patientyears for basal cell carcinoma, and 371 patients with 915 patient-years of follow-up for squamous cell carcinoma were recruited. Risk factors for recurrence included age, non-primary tumours and more stages or unfinished surgeries for both tumours, and immunosuppression for squamous cell carcinoma. Incidence rates of recurrence were 1.3 per 100 person-years for basal cell carcinoma (95% confidence interval 1.1-1.5) and 4.5 for squamous cell carcinoma (95% confidence interval 3.3-6.1), being constant over time (0-5 years). In conclusion, follow-up strategies should be equally intense for at least the first 5 years, with special attention paid to squamous cell carcinoma (especially in immunosuppressed patients), elderly patients, non-primary tumours, and those procedures requiring more stages, or unfinished surgeries.

Palabras clave